Enorama Pharma AB (SE:ERMA)
:ERMA
Want to see SE:ERMA full AI Analyst Report?
Top Page
Enorama Pharma AB
(ERMA)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr0.33
▼(-82.88% Downside)
Action:Reiterated
Date:05/23/26
The score is primarily weighed down by weak financial performance (declining small revenue base, heavy losses, negative equity, and ongoing cash burn). Technicals provide only partial support via short-term strength versus the 20/50-day averages, but the longer-term downtrend and negative MACD limit the benefit. Valuation remains challenged due to unprofitable earnings and no dividend support.
Positive Factors
Partnering/licensing business model
A partner-led commercialization model lets Enorama focus R&D and formulation work while shifting large-scale manufacturing, distribution and marketing costs to partners. Over months this lowers capex needs, speeds market access if partnered, and creates scalable royalty/milestone revenue potential without building a full sales infrastructure.
Negative Factors
Persistent cash burn
Sustained negative operating and free cash flow means the company requires external financing to fund operations and development. Over a 2-6 month horizon this elevates dilution or funding risk, limits runway for clinical/regulatory progress, and constrains the ability to invest in commercialization without partner support.
Read all positive and negative factors
Positive Factors
Negative Factors
Partnering/licensing business model
A partner-led commercialization model lets Enorama focus R&D and formulation work while shifting large-scale manufacturing, distribution and marketing costs to partners. Over months this lowers capex needs, speeds market access if partnered, and creates scalable royalty/milestone revenue potential without building a full sales infrastructure.
Read all positive factors
Enorama Pharma AB (ERMA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr27.15M
Dividend YieldN/A
Average Volume (3M)4.35K
Price to Earnings (P/E)―
Beta (1Y)0.68
Revenue Growth-86.56%
EPS Growth8.75%
CountrySE
Employees5
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.91
Shares Outstanding74,588,684
10 Day Avg. Volume2,975
30 Day Avg. Volume4,348
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)-5.66
Price to Sales (P/S)48.45
P/FCF Ratio-2.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Enorama Pharma AB Business Overview & Revenue Model
Company Description
Enorama Pharma AB (publ) is a Swedish pharmaceutical enterprise primarily engaged in the creation, production, and distribution of specialized chewing gums. These products are formulated with established generic active ingredients. The company's o...
How the Company Makes Money
Enorama Pharma AB’s business model is primarily based on developing proprietary nicotine replacement therapy products and monetizing them through partnering and commercialization arrangements rather than building a large standalone consumer sales ...
Enorama Pharma AB Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
22
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.18M | 2.74M | 15.77M | 1.36M | 6.85M | 11.04M |
| Gross Profit | -45.16M | -62.12M | 3.70M | -3.90M | -616.00K | 2.13M |
| EBITDA | -57.68M | -61.65M | -20.41M | -43.05M | -37.22M | -26.28M |
| Net Income | -65.27M | -75.14M | -43.81M | -44.61M | -41.78M | -28.54M |
Balance Sheet | ||||||
| Total Assets | 22.95M | 8.26M | 15.89M | 34.38M | 48.72M | 50.93M |
| Cash, Cash Equivalents and Short-Term Investments | 17.76M | 3.04M | 2.08M | 6.15M | 4.14M | 12.20M |
| Total Debt | 0.00 | 0.00 | 0.00 | 436.00K | 1.91M | 3.79M |
| Total Liabilities | 59.58M | 31.71M | 8.09M | 14.85M | 17.20M | 29.58M |
| Stockholders Equity | -36.63M | -23.45M | 7.80M | 19.54M | 31.52M | 21.35M |
Cash Flow | ||||||
| Free Cash Flow | -45.27M | -59.26M | -35.70M | -41.35M | -32.96M | -31.99M |
| Operating Cash Flow | -45.27M | -59.26M | -35.70M | -41.35M | -32.96M | -30.16M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.82M |
| Financing Cash Flow | 54.65M | 50.69M | 35.29M | 41.86M | 25.34M | 39.51M |
Enorama Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:ERMA
Enorama Pharma AB
0.34
-2.05
-85.81%
DE:AC6
AlzeCure Pharma AB
0.43
0.25
130.32%
DE:6FN
Klaria Pharma Holding AB
0.07
0.03
100.00%
DE:40M
Nanexa AB
0.38
0.17
79.34%
SE:ENZY
Enzymatica AB
2.60
-0.35
-11.86%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.